financetom
Business
financetom
/
Business
/
Defence firm Saab raises sales outlook after Q1 profit jump
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Defence firm Saab raises sales outlook after Q1 profit jump
Apr 26, 2024 12:08 AM

*

SAAB Q1 operating profit up 28% on the back of strong

demand

*

Raises full-year organic growth forecast to 15-20%

*

Geopolitical turmoil, NATO accession drivers behind growth

(Rewrites, adds details and CEO quotes in paragraphs 3-4, 6-10)

By Johan Ahlander

STOCKHOLM, April 26 (Reuters) - Swedish defence

equipment maker Saab reported on Friday a 28% rise in

first-quarter operating profit and raised its organic sales

growth forecast on the back of strong demand amid Sweden's NATO

accession.

Operating profit at the maker of the Gripen fighter jet was

1.19 billion crowns ($109 million), compared with 928 million a

year earlier.

"We are doing very well in the market," CEO Micael Johansson

told Reuters. "We have a strong order intake, a lot of medium

and small orders that are increasing, which is great as a basis

for the company."

Saab raised its organic sales growth forecast for 2024 to

15-20% from 12-16% previously.

The company, which competes with U.S. defence giant Lockheed

Martin ( LMT ), France's Dassault and Britain's BAE Systems

, has seen strong demand for its products over the past

year due to geopolitical turmoil and Sweden's accession to NATO.

Johansson said Sweden's membership meant that the company

now was able to participate in the alliance's tender processes.

"We have received at least three orders for support weapons

and Robot-70s from that body. We had difficulty accessing that

when we were not members," he said.

Saab's support weapons include man-portable anti-tank

weapons, while Robot-70 is an air defence system.

Order bookings increased to 18.5 billion crowns in the

quarter from 17.0 billion last year. Its order backlog increased

to 158 billion crowns from 133 billion.

Saab is in the process of ramping up production to cope with

the demand and backlog. It recruited nearly 2,500 employees and

increased capital expenditure by more than 50% in 2023, and

added another 725 people in the first quarter of this year.

($1 = 10.8794 Swedish crowns)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Strathcona Resources Rating Affirmed, Withdrawn by Fitch
Strathcona Resources Rating Affirmed, Withdrawn by Fitch
Jul 12, 2024
11:00 AM EDT, 07/12/2024 (MT Newswires) -- Fitch Ratings on Friday said it affirmed Strathcona Resources' ( STHRF ) long-term issuer default rating at B+ with a stable outlook. Also, the rating agency affirmed the company's first lien-secured revolving credit facility at BB+/RR1 and upgraded the senior unsecured bond to B+/RR4 from B/RR5. After these actions, Fitch withdrew the issuer...
ConocoPhillips-Marathon Merger Hits Hurdle: FTC Requests More Info, Delays Deal
ConocoPhillips-Marathon Merger Hits Hurdle: FTC Requests More Info, Delays Deal
Jul 12, 2024
On Thursday, ConocoPhillips ( COP ) and Marathon Oil Corporation ( MRO ) received a Second Request from the Federal Trade Commission (FTC) to extend the Hart-Scott-Rodino waiting period. The merger will proceed after the FTC review and fulfillment of other conditions in the merger agreement. ConocoPhillips ( COP ) and Marathon are working with the FTC on its review...
Biogen, Eisai Get Approval for Leqembi in Israel for Treatment of Alzheimer's Disease
Biogen, Eisai Get Approval for Leqembi in Israel for Treatment of Alzheimer's Disease
Jul 12, 2024
10:48 AM EDT, 07/12/2024 (MT Newswires) -- Biogen (BIIB) and Eisai said Friday that the Leqembi has been approved in Israel for the treatment of patients with Alzheimer's disease. The drug should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, according to the joint statement. Leqembi's approval is based on results from the phase...
Wells Fargo Second-Quarter Net Interest Income Misses Expectations; Stock Falls Intraday
Wells Fargo Second-Quarter Net Interest Income Misses Expectations; Stock Falls Intraday
Jul 12, 2024
10:54 AM EDT, 07/12/2024 (MT Newswires) -- Wells Fargo ( WFC ) results rose above market expectations for the second quarter, but the lender's net interest income declined annually and fell short of analysts' estimates. Earnings increased to $1.33 a share for the quarter through June 30 from $1.25 a year earlier, the banking giant said Friday, compared with the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved